e-learning
resources
Amsterdam 2015
Wednesday, 30.09.2015
Cellular and molecular mechanisms of COPD and emphysema
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Elastase-induced emphysema is attenuated by L-carnitine supplementation
Thomas Conlon (Neuherberg, Germany), Thomas Conlon, Cornelia Prehn, Jerzy Adamski, Oliver Eickelberg, Ali Önder Yildirim
Source:
International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Session:
Cellular and molecular mechanisms of COPD and emphysema
Session type:
Poster Discussion
Number:
5057
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Thomas Conlon (Neuherberg, Germany), Thomas Conlon, Cornelia Prehn, Jerzy Adamski, Oliver Eickelberg, Ali Önder Yildirim. Elastase-induced emphysema is attenuated by L-carnitine supplementation. Eur Respir J 2015; 46: Suppl. 59, 5057
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Temporal profile of metaloproteases gene expression in elastase-induced emphysema
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Effect of MSC treatment on LPS-induced inflammation, emphysema and atherosclerosis in E3L mice
Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease
Year: 2015
Galectin-9 attenuates elastase-induced emphysema by reducing neutrophil chemotaxis in mice
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Acid sphingomyelinase deficiency improves lung function in allergen-induced asthma in mice
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014
Animal models of pulmonary emphysema: a stereologist's perspective
Source: Eur Respir Rev 2006; 15: 136-147
Year: 2006
Dilatation reserve of pulmonary arteries at stages of COPD experimental model
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
A novel non-human primate model of cigarette smoke-induced chronic obstructive pulmonary disease
Source: International Congress 2014 – Animal models: asthma, COPD and beyond
Year: 2014
The effect of lipopolysaccharide-contaminated ovalbumin on airway inflammation and remodeling in a chronic murine asthma model
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
High fructose intake increases alveolar enlargement and muscle inflammation in mice exposed to cigarette smoke
Source: International Congress 2016 – New signalling pathways in COPD
Year: 2016
Effects of tobacco smoke and poly IC, alone and in combination, on mouse lung pathology
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
LATE-BREAKING ABSTRACT: Research of large aperture fenestration emphysema model in pigs
Source: International Congress 2016 – Clinical characteristics of asthma
Year: 2016
Does Rosemary leaves extract can attenuate lung injury in experimental pulmonary fibrosis in rats?
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
The role of lL-17 in the OVA-LPS driven model of lung inflammation
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Implication of interleukin-10 in the development of COPD induced by cigarette smoke exposure in mice
Source: Annual Congress 2013 –COPD: experimental biology
Year: 2013
Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept